CPMP Recommends Stryker OP-1 For European Market Clearance

The clinical data supporting Stryker's Osteogenic Protein 1 (OP-1) showed the radiographic healing results of the treatment group to be "slightly inferior" to the autograft control group, CPMP concluded in its recommendation for European market authorization.